StockData

Endonovo Therapeutics, Inc. (ENDV) stock

ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $135.08KP/E –Yield –

Earnings

Endonovo Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Endonovo Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Endonovo Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Endonovo Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Endonovo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. 8-K exhibit EX-99.1
    News

See a number that looks wrong?